Purpose: To identify pre-therapeutic variables associated with overall survival (OS) Ra injections had a median OS of 5.9 months (95% CI 3.8-8.1; P < 0.001). Univariable analysis showed poor baseline ECOG performance status (PS), baseline opioid use, lowered baseline hemoglobin, and elevated prostatespecific antigen, alkaline phosphatase and lactate dehydrogenase (LD) levels were significantly associated with OS. Multivariable Cox regression analysis demonstrated that poor baseline ECOG PS (HR 10.6) and high LD levels (HR 7.7) were pre-therapeutic variables that predicted poor OS. Conclusions: In a multivariable Cox regression model, good baseline ECOG PS and low LD levels were significantly associated with longer OS in patients treated with 223 Ra. These variables may be used for stratification of CRPC patients for 223 Ra therapy. Prospective studies to evaluate these variables are warranted, to develop a nomogram to select patients properly. In this retrospective study, predictors of overall survival in 45 metastatic castration-resistant prostate cancer patients treated with 223 Ra therapy were evaluated. Baseline ECOG performance status and lactate dehydrogenase levels turned out to be significant in a multivariable prediction model for overall survival.
R
a is a registered palliative therapy for castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases. This radioisotope is very similar to calcium and binds selectively to areas of increased bone turnover in bone metastases. There it emits high-energy alpha particles of short range (<100 μm; 2-10 cell layers), causing double-strand DNA breaks leading to a cytotoxic effect on tumor cells and cells in the tumor microenvironment. 1, 2 In the phase 3 ALSYMPCA trial, CRPC patients were treated with 223 Ra or placebo, either before or after docetaxel chemotherapy. 3 The outcome was a significant median overall survival (OS) benefit of 3.6 months in favor of 223 Ra over placebo. Subsequent analyses demonstrated survival benefit of 223 Ra in chemotherapynaïve CRPC patients as well as in post-chemotherapy CRPC patients. 4 In addition, 223 Ra reduced the risk of symptomatic skeletal events and was accompanied by significant improvement of quality of life. 5, 6 To date, clinical data on 223 Ra in daily practice is scarce. In the ALSYMPCA trial, 63% of CRPC patients treated with 223 Ra received six injections, whereas only 42% of the Dutch patients received six 223 Ra injections in 2016, with a median number of four injections. 3 This may indicate that real-world patients treated with 223 Ra differ from those included in the ALSYMPCA trial. 7 In addition, effect monitoring during 223 Ra therapy is challenging. Therefore, optimal patient selection is crucial. It is important to identify pre-therapeutic factors to estimate whether a patient will achieve OS benefit of 223 Ra. Knowledge of these factors can lead to better patient selection and might lead to a reduction of health care costs. The objective of this study was to evaluate realworld data of CRPC patients treated with 223 Ra, in order to determine pre-therapeutic variables that predict OS and to describe baseline differences between patients who completed and patients who discontinued 223 Ra therapy. Ra injection were included in the study. There were no exclusion criteria. All patients continued androgen deprivation therapy and patients were castration-resistant according to the European Association of Urology definition. 8 The medical records of the patients were reviewed to collect information about demographic characteristics, comorbidity, histology, surgical procedures and medical therapies for prostate cancer, laboratory evaluations, imaging studies, the occurrence of skeletal related events (SREs) and survival. All patients were followed until death or June 1, 2017.
PATIENTS AND METHODS

Study Design and Patient Population
223
Ra Therapy Standard of Care
Ra was injected intravenously every 4 weeks up to six cycles according to standard of care. 9 Institutional criteria for initiation of 223 Ra therapy included CRPC patients with bone metastases, no or small (<3 cm in short-axis diameter) lymph node metastases and no visceral metastases. Laboratory requirements were baseline absolute neutrophil count >1. 
Adverse Events
Adverse events during 223 Ra therapy were scored using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. SREs were defined as symptomatic fracture, radiation or surgery to bone, or spinal cord compression. 10 
Biochemical and Radiological Response Evaluation
Changes in PSA and ALP were calculated from baseline to week 12 (after three injections), from baseline to end of therapy (approximately 1 month after the last injection) and as maximal percentage change at any time from baseline. Patients who had no baseline level, no follow-up measurements or received concomitant enzalutamide or abiraterone were excluded from biochemical response evaluation. More than 25% decline or increase from baseline of PSA, ALP and LD was considered to be clinically significant, according to Prostate Cancer Working Group 3 criteria. 10 Radiological evaluation was performed in patients who underwent evaluation of soft tissues within 3 months after completion or discontinuation of therapy.
Statistical Methods
Survival time was defined as the time interval from date of first 223 Ra injection to the date of death. Cox proportional hazards models were used to assess the prognostic significance of baseline variables in univariable and multivariable analysis. A multivariable Cox regression model was fitted by including variables in the model with a forward selection strategy based on Wald's test at a significance level of 0.10 at every step. In case baseline variables were heavily skewed distributed or the proportional hazard assumption was not likely to hold, log transformation or categorization of variables was performed.
To compare baseline characteristics between patients who completed and discontinued 223 Ra therapy, the chi-square test or Fisher exact test was used. Statistical tests were performed twosided, with P values <0.05 considered statistically significant.
Survival curves for patients who completed therapy and patients who discontinued therapy were estimated by the Kaplan-Meier estimator. The Mantel-Cox log rank test was used to compare the survival distributions.
Statistical analyses were performed using SPSS 22.0 (IBM®, Armonk, NY, USA). Figures were created with SPSS and GraphPad Prism 5.03 (GraphPad Software, Inc., La Jolla, CA, USA).
Ethics
This study was approved by the medical ethics review committee. The principles of the Helsinki Declaration were followed.
RESULTS
Patient Characteristics
Patient characteristics of the 45 CRPC patients who received 223 Ra are shown in Table 1 . The median number of prior registered therapies for CRPC was 2 (range 0-4). Twenty-five patients (56%) received prior docetaxel chemotherapy and 35 patients (78%) received prior enzalutamide and/or abiraterone. Baseline laboratory and imaging characteristics are described in Table 2 .
Overall Survival
Thirty-eight patients (84%) had died at time of analysis. The median OS since start of 223 Ra in the whole study population was 13.0 months (95% CI 8.2-17.8). Univariable analysis showed that baseline ECOG PS, baseline opioid use and baseline hemoglobin, PSA, ALP and LD levels were variables significantly associated with OS (Table 3) . With the multivariable analysis we found a model that included baseline ECOG PS and baseline LD levels (Table 4) . However, the multivariable analysis was restricted to 32 subjects (71%) due to limited availability of baseline LD levels (complete case analysis). When the baseline LD level variable was left out from analysis, 41 subjects (91%) were included in the analysis and baseline ECOG PS, baseline hemoglobin level and opioid use were selected in multivariable analysis (hazard ratios 2.6 (95% CI 1.1-5.8); 0.8 (95% CI 0.6-1.0) and 2.2 (95% CI 1.0-4.7), respectively).
The Number of Injections
Twenty-one (47%) patients received all six injections. The median number of injections was five. Four patients (9%) received one or two injections, seven patients (16%) received three injections, four patients (9%) received four injections and nine patients (20%) received five injections. We found significant differences between patients who received one to five injections and those who completed therapy regarding baseline LD levels, baseline opioid use and prior use of abiraterone or enzalutamide (Tables 1 and 2) . Patients who completed 223 Ra therapy had a median OS of 19.7 months (95% CI 14.9-24.6), while patients who received one to five 223 Ra injections had a median OS of 5.9 months (95% CI 3.8-8.1; P < 0.001) (Fig. 1) . This significant finding in survival was substantiated by the OS difference between five (n = 9) and six 223 Ra injections (7.3 vs 19.7 months, P < 0.01).
Adverse Events
Persistent hematologic toxicity was the reason to discontinue 223 Ra therapy in nine of 24 patients (38%; pancytopenia in four patients, thrombocytopenia in three patients, anemia in two patients). No grade 3-4 non-hematologic adverse events occurred during and after therapy.
At baseline, 33 patients (73%) had grade 1 anemia and five patients (11%) had grade 2 anemia. Only one patient with initial grade 2 anemia completed therapy. During therapy, 16 At least one time irradiated on metastases (all axial skeleton, one also appendicular skeleton). †Percentages may not sum to 100 due to rounding. ‡Calculated by two-sided Fisher exact probability test.
ADT indicates androgen deprivation therapy; CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology Group; PCa, prostate cancer. 1.000 ‡ Bold = P < 0.05. *Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity. †Percentages may not sum to 100 due to rounding. ‡Calculated by two-sided Fisher exact probability test.
ALP indicates alkaline phosphatase; ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group performance score; Hb, hemoglobin; LD, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; PSA, prostate-specific antigen; WBC, white blood cell.
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received red blood cell transfusion. Seventy-five percent of these patients did not complete therapy and 81% of these patients had received two or more prior CRPC therapies. OS was significantly worse when compared to patients who did not need blood cell transfusion (8 versus 14 months). At any time during therapy, grade 1 thrombocytopenia occurred in 11 patients (24%) and grade 2 Physical health deterioration was the reason to stop therapy in six (25%) patients. Five of these six patients had a baseline ECOG PS of 1 (33%) or 2 (50%).
During therapy, 14 SREs were reported in 11 patients (24%). In seven patients spinal cord compression occurred, which was treated by external beam radiotherapy (EBRT) plus dexamethasone. In two patients a pathological fracture occurred; these patients both discontinued therapy. Additionally, three patients underwent EBRT because of increase of pain at a solitary lesion. Ra monotherapy. Significant increase of PSA was observed in 65% of patients after three injections. Significant decrease of ALP was found in 53% of patients after three injections. All of the patients with PSA decrease showed remarkable ALP decrease (range 23%-75%). ALP at end of therapy was significantly lower in patients who completed therapy when compared to patients who discontinued therapy (P < 0.01).
Biochemical Response Evaluation
Radiological Response Evaluation
In retrospect, four patients (10%) had small visceral metastases in either liver (n = 2) or lungs (n = 2) prior to start of 223 Ra therapy. The two patients with lung metastases completed 223 Ra therapy, while both patients with liver metastases discontinued therapy after the fourth injection.
After 223 Ra therapy, 20 patients (44%) underwent evaluation of lymph nodes and soft tissues. Radiological evaluation was mainly performed in patients that completed therapy (90% versus 38%). New lymph node enlargement (≥15 mm in the short axis) was shown in 17% of patients. New visceral metastases to liver, lung, spleen and/or brain were found in 41% of patients. All of these patients were heavily pretreated. Among the 24 patients who discontinued therapy, radiological disease progression was the main reason to stop therapy in five (21%) patients.
Therapies After
223
Ra Therapy
In patients who discontinued 223 Ra therapy, best supportive care (67%) or a second-generation anti-hormonal agent (33%) was started. In patients who completed 223 Ra therapy, subsequent therapy was a second-generation anti-hormonal agent in 15 patients (71%). Two patients (10%) received docetaxel without any toxicity during chemotherapy and three patients (14%) received best supportive care after completion of 223 Ra therapy.
DISCUSSION
Overall Survival
Median OS in this cohort was 13.0 months, which is similar to the ALSYMPCA trial. 3 Multivariable analysis selected baseline ECOG PS and LD levels to be significantly associated with OS in this study. The post hoc multivariable analysis of the ALSYMPCA trial also selected baseline ECOG PS and LD were correlated with OS. In addition, that analysis identified albumin level, total ALP, PSA and age to be correlated with OS as well. 11 The analysis of 
